Paleolithic Diet in the Treatment of Diabetes Type 2 in Primary Health Care
1 other identifier
interventional
13
1 country
1
Brief Summary
There is uncertainty about the optimal diet in the prevention and treatment of diabetes type 2. Earlier studies have generally focused on intakes of fat, protein, carbohydrate, fiber, fruit and vegetables. This study is based on another approach which compares foods that were available during human evolution with more recently introduced ones. The basic tenet from evolutionary biology is that if human physiology is less adapted to a relatively recently introduced diet based on agriculture, this could cause disturbances to human physiology and ultimately lead to diseases. Epidemiological studies indicates that diabetes mellitus type 2 is absent or near absent in populations eating a Palaeolithic ("Old Stone Age") diet which is free from food items produced in agriculture or the food industry. Our study hypothesis is that a Palaeolithic diet is better than the standard diabetes diet recommended today in treating diabetes type 2. Fifteen patients with diabetes type 2 have been randomized to
- 1.a Palaeolithic diet based on lean meat, fish, fruit, vegetables, root vegetables, eggs, and nuts
- 2.a standard diabetes diet as recommended by national health authorities.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_2 diabetes-mellitus-type-2
Started Jan 2005
Longer than P75 for phase_2 diabetes-mellitus-type-2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2005
CompletedFirst Submitted
Initial submission to the registry
February 13, 2007
CompletedFirst Posted
Study publicly available on registry
February 14, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2007
CompletedMay 15, 2008
May 1, 2008
2.7 years
February 13, 2007
May 13, 2008
Conditions
Outcome Measures
Primary Outcomes (5)
area under the curve for glucose (AUC Glucose0-120) at the oral glucose tolerance test at baseline, 3 months and 6 months
area under the curve for insulin (AUC Insulin0-120) at the oral glucose tolerance test at baseline, 3 months and 6 months
HbA1C at baseline, 3 months and 6 months
weight at baseline, 3 months and 6 months
waist circumference at baseline, 3 months and 6 months
Secondary Outcomes (7)
satiation measured on visual semi-analogous scale at food intake during 4 days av 6 weeks and 12 weeks
leptin at baseline, 3 months and 6 months
fasting plasma glucose at baseline, 3 months and 6 months
fasting plasma insulin at baseline, 3 months and 6 months
Systolic and diastolic blod pressure at baseline, 3 months and 6 months
- +2 more secondary outcomes
Interventions
Eligibility Criteria
You may qualify if:
- Adults with capacity to perform study
- Diabetes Mellitus Type 2
- C-peptide \> 0
- HbA1C \>5.5
- Unchanged diabetes treatment during last 3 months
- Weight and HbA1C varied less than 5% during last 3 months
- No acute heart disease during last 6 months
- Unchanged treatment with betablocker last 6 months
- Unchanged treatment with thyroid hormone substitution last 6 months
You may not qualify if:
- Treatment with insulin
- Chronic treatment with steroids (not inhaled)
- Treatment with Waran (anticoagulant cumarin type)
- Creatinin \> 130 micromol/L
- Elevated liver enzymes (ALAT,ASAT,ALP or GT \> 4 X upper reference value)
- Acute heart disease
- Changed treatment with betablocker or thyroid hormone substitution
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Lund University Hospital
Lund, Skåne County, 22185, Sweden
Related Publications (6)
Jonsson T, Ahren B, Pacini G, Sundler F, Wierup N, Steen S, Sjoberg T, Ugander M, Frostegard J, Goransson L, Lindeberg S. A Paleolithic diet confers higher insulin sensitivity, lower C-reactive protein and lower blood pressure than a cereal-based diet in domestic pigs. Nutr Metab (Lond). 2006 Nov 2;3:39. doi: 10.1186/1743-7075-3-39.
PMID: 17081292BACKGROUNDJonsson T, Olsson S, Ahren B, Bog-Hansen TC, Dole A, Lindeberg S. Agrarian diet and diseases of affluence--do evolutionary novel dietary lectins cause leptin resistance? BMC Endocr Disord. 2005 Dec 10;5:10. doi: 10.1186/1472-6823-5-10.
PMID: 16336696BACKGROUNDCordain L, Eaton SB, Sebastian A, Mann N, Lindeberg S, Watkins BA, O'Keefe JH, Brand-Miller J. Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr. 2005 Feb;81(2):341-54. doi: 10.1093/ajcn.81.2.341.
PMID: 15699220BACKGROUNDFontes-Villalba M, Granfeldt Y, Sundquist K, Memon AA, Hedelius A, Carrera-Bastos P, Jonsson T. Effects of a Paleolithic diet compared to a diabetes diet on leptin binding inhibition in secondary analysis of a randomised cross-over study. BMC Endocr Disord. 2024 Sep 4;24(1):176. doi: 10.1186/s12902-024-01715-0.
PMID: 39232748DERIVEDFontes-Villalba M, Lindeberg S, Granfeldt Y, Knop FK, Memon AA, Carrera-Bastos P, Picazo O, Chanrai M, Sunquist J, Sundquist K, Jonsson T. Palaeolithic diet decreases fasting plasma leptin concentrations more than a diabetes diet in patients with type 2 diabetes: a randomised cross-over trial. Cardiovasc Diabetol. 2016 May 23;15:80. doi: 10.1186/s12933-016-0398-1.
PMID: 27216013DERIVEDJonsson T, Granfeldt Y, Ahren B, Branell UC, Palsson G, Hansson A, Soderstrom M, Lindeberg S. Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study. Cardiovasc Diabetol. 2009 Jul 16;8:35. doi: 10.1186/1475-2840-8-35.
PMID: 19604407DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Tommy Jönsson, MD
Department of Clinical Sciences, Lund University, Lund Sweden
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
February 13, 2007
First Posted
February 14, 2007
Study Start
January 1, 2005
Primary Completion
September 1, 2007
Study Completion
September 1, 2007
Last Updated
May 15, 2008
Record last verified: 2008-05